April 5, 2018
On April 5, Health Canada approved Apobiologix's pegfilgrastim biosimilar Lapelga. This marks the first pegfilgrastim biosimilar approved in Canada and the world.
Lapelga is a biosimilar of Amgen's Neulasta (pegfilgrastim). It is indicated in Canada to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drugs.
2400 North Commerce Parkway,
Weston, Florida 33326